EuroBiotech Report—Cancer biotechs raise cash, NLS touts ADHD data and Sanofi retools ImmunoGen collaboration

europeGOOD

Welcome to the latest edition of our weekly EuroBiotech Report. We start this week with funding rounds at two European cancer biotechs. Bicycle Therapeutics secured the biggest boost to its finances, pulling in £40 million ($51 million) to take its lead drug into the clinic. Inthera Bioscience, like Bicycle, is going after solid tumors but is one step behind in development. The Swiss biotech tapped Merck Ventures, Novo Seeds and others for $10.8 million to advance its lead program to the cusp of phase 1. Fellow Swiss firm NLS Pharma was also in the news this week. The company posted clinical data that support the advance of its ADHD candidate into late-stage tests. Sanofi retooled its cancer collaboration with ImmunoGen. And more. Nick Taylor

1. Bicycle raises £40M to take cancer drugs into the clinic

Bicycle Therapeutics has returned to its big name backers for £40 million ($51 million) to fund the advance of cancer candidates into the clinic. The round equips Bicycle to find out how its targeted, tumor-penetrating delivery vehicles fare when administered to patients with solid tumors.

Whitepaper

Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

2. Merck Ventures leads $11M round in solid tumor startup

Merck Ventures has led a $10.8 million (€9.6 million) investment in Inthera Bioscience. The series A sets the Swiss biotech up to wrap up preclinical development of a lead candidate against cancers associated with human papillomavirus (HPV).

3. Swiss biotech NLS touts positive ADHD data, plots late-stage tests

NLS Pharma has posted some positive data for its ADHD candidate mazindol CR, which it hopes will have better luck than in did for obesity and narcolepsy after it was pulled off the market. 

4. ImmunoGen gets $30M amid Sanofi ADC deal shake-up

The pair have a deal that stretches all the way back to 2003, but today ImmunoGen and French Big Pharma Sanofi are retooling their cancer collaboration.

And more articles of note >>

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.